320 related articles for article (PubMed ID: 25790297)
1. Serum interferon-related microRNAs as biomarkers to predict the response to interferon therapy in chronic hepatitis C genotype 4.
Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
PLoS One; 2015; 10(3):e0120794. PubMed ID: 25790297
[TBL] [Abstract][Full Text] [Related]
2. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
[TBL] [Abstract][Full Text] [Related]
3. Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.
Su TH; Liu CH; Liu CJ; Chen CL; Ting TT; Tseng TC; Chen PJ; Kao JH; Chen DS
Proc Natl Acad Sci U S A; 2013 May; 110(19):7844-9. PubMed ID: 23613588
[TBL] [Abstract][Full Text] [Related]
4. IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.
Estrabaud E; Appourchaux K; Bièche I; Carrat F; Lapalus M; Lada O; Martinot-Peignoux M; Boyer N; Marcellin P; Vidaud M; Asselah T
PLoS One; 2015; 10(4):e0121395. PubMed ID: 25844942
[TBL] [Abstract][Full Text] [Related]
5. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
[TBL] [Abstract][Full Text] [Related]
6. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
7. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
Estrabaud E; Lapalus M; Broët P; Appourchaux K; De Muynck S; Lada O; Martinot-Peignoux M; Bièche I; Valla D; Bedossa P; Marcellin P; Vidaud M; Asselah T
J Virol; 2014 Jun; 88(11):6394-402. PubMed ID: 24672032
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients.
Motawi TM; Rizk SM; Shaker OG; Mokhtar OZ
PLoS One; 2015; 10(3):e0121524. PubMed ID: 25811198
[TBL] [Abstract][Full Text] [Related]
9. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
Al-Ashgar HI; Khan MQ; Helmy A; Al-Thawadi S; Al-Ahdal MN; Khalaf N; Al-Qahtani A; Sanai FM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):404-10. PubMed ID: 23470264
[TBL] [Abstract][Full Text] [Related]
10. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
11. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
12. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
13. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
[TBL] [Abstract][Full Text] [Related]
14. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
Harrison SA; Rossaro L; Hu KQ; Patel K; Tillmann H; Dhaliwal S; Torres DM; Koury K; Goteti VS; Noviello S; Brass CA; Albrecht JK; McHutchison JG; Sulkowski MS
Hepatology; 2010 Sep; 52(3):864-74. PubMed ID: 20568303
[TBL] [Abstract][Full Text] [Related]
15. Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.
van Vlerken LG; Huisman EJ; van Soest H; Boland GJ; Drenth JP; Siersema PD; Burger DM; van Erpecum KJ
J Viral Hepat; 2012 Jan; 19(1):39-46. PubMed ID: 21114586
[TBL] [Abstract][Full Text] [Related]
16. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection.
Waidmann O; Bihrer V; Kronenberger B; Zeuzem S; Piiper A; Forestier N
Dig Liver Dis; 2012 May; 44(5):438-41. PubMed ID: 22209627
[TBL] [Abstract][Full Text] [Related]
18. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
[TBL] [Abstract][Full Text] [Related]
19. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
Males S; Gad RR; Esmat G; Abobakr H; Anwar M; Rekacewicz C; El Hoseiny M; Zalata K; Abdel-Hamid M; Bedossa P; Pol S; Mohamed MK; Fontanet A
Antivir Ther; 2007; 12(5):797-803. PubMed ID: 17713163
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
